CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 96 enrolled
Drug / intervention
GLP-1 analogue - semaglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04779697
NCT04779697Phase 1Completed
CompareCT.gov

GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight

Yale University·interventional·Posted Mar 3, 2021·Updated Feb 10, 2026

In Brief

A Phase 1 clinical trial evaluating GLP-1 analogue - semaglutide and Placebo for Obesity. Completed, enrolled 96 participants across 1 site.

Detailed Summary

To examine response to a glucagon-like peptide-1 analogue vs. placebo in patients with obesity and assess impact on craving, hunger, stress, and weight outcomes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedMar 3, 2021
Enrollment StartFeb 1, 2021
Primary CompletionNov 19, 2024
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 5.3 years ago

Interventions

GLP-1 analogue - semaglutidedrug

GLP-1 analogue - semaglutide - administered once weekly for a total of 12 weeks

Placeboother

Placebo - administered once weekly for a total of 12 weeks